Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
China Financing Commercial

Chinese Biotech Financing Rebounds But Mega Deals Missing

  • Analysis

Executive Summary

Ten Chinese biotechs raised at least a combined $221m in venture capital and private equity deals after the turn of the year.

You may also be interested in...



Asia Deal Watch: Avenue Takes On AnnJi’s Spinal And Bulbar Muscular Atrophy Candidate

Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.

Latest Big Rounds Herald A China Biotech Funding Spring?

Around the turn of the year, four Chinese biotechs including Kelun Biotech and BioRay ramped up funding with deals worth more than $100m, at a time when overall investment sentiment in the sector remains gloomy.

Oncology, Cell Therapy Developers Bag $175m In China

Investors continue to focus on anticancer therapies including small molecule drugs and cell therapies in China.

Table

View full table

Topics

Related Companies

Tags:
China Financing Commercial
Latest Headlines

Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy

Pipeline Watch - ADD Meeting Dominates Phase III Readouts

Path Ahead For Neuraly’s NLY01 Unclear After Phase II Parkinson’s Disappointment

Women’s Health Still Key to Bayer Despite Early Research Shift

See All
UsernamePublicRestriction

Register

SC147967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By